Could diabetes drugs fix anemia in kidney disease?
NCT ID NCT07334145
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test whether SGLT2 inhibitors, a type of diabetes drug, can help correct anemia in people with chronic kidney disease (CKD). Anemia is common in CKD and often requires iron or hormone injections, which have side effects. The trial will enroll 60 adults with CKD stages 1-4 and mild anemia, measuring changes in hemoglobin levels over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SGLT2 inhibitors (dapagliflozin or empagliflozin)
- What this could lead to
- If successful, this could offer a new way to manage anemia in CKD patients, potentially reducing the need for iron or ESA injections.
- What could go wrong
- This is a small, early-stage trial with only 60 participants. The effect on anemia may be modest or not clinically significant, and there are known risks like dehydration or diabetic ketoacidosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sohag University Hospital
Sohag, Sohag University, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less be more? testing transfusion limits in ECMO
- Aging kidneys under the microscope: could a simple test predict failure?
- A simple blood test trend may flag ICU patients at risk
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Rethinking anemia: does blood hemoglobin tell the whole story?